# BPC-157 Mechanism of Action: VEGFR2-Akt-eNOS and the Nitric-Oxide System | BPC-157 > BPC-157 mechanism of action: VEGFR2 up-regulation and internalization feeding Akt-eNOS nitric-oxide signaling, with FAK-paxillin, growth-hormone-receptor, and vasomotor routes. Linear PK, elimination half-life under 30 minutes. Cited. The repair effects of the pentadecapeptide trace, most consistently, to angiogenesis driven by VEGFR2 — with corroborating nitric-oxide, fibroblast-migration, and growth-hormone-receptor routes, and a pharmacokinetic spine that clears in under 30 minutes. ## The lead channel: VEGFR2 up-regulation and internalization BPC-157 mechanism of action is best characterized as pro-angiogenic cytoprotection, and the lead channel is VEGFR2. The peptide up-regulates VEGFR2 expression and promotes the receptor's internalization, which activates the downstream VEGFR2-Akt-eNOS pathway [3]. Across a chick chorioallantoic-membrane model, a rat hindlimb-ischemia model, and human vascular endothelial cells, this raised vessel density in vivo and in vitro and accelerated blood-flow recovery in ischemic muscle [3]. The causal test is the load-bearing detail: when endocytosis was inhibited, the angiogenic effect was blocked [3]. That places receptor internalization — not merely receptor binding — at the center of the mechanism, and it is why the literature describes VEGFR2 "up-regulation and internalization" as a unit rather than VEGFR2 activation alone. eNOS, endothelial nitric oxide synthase, is the enzyme at the end of that chain, producing the vascular nitric oxide that the repair response runs on. ## The corroborating routes: nitric oxide, FAK-paxillin, GH receptor Around the VEGFR2 spine, several routes corroborate and extend the angiogenic story. BPC-157 modulates vasomotor tone through the Src-Caveolin-1-eNOS pathway, a vascular and endothelial mechanism that complements its VEGFR2 activity [9]. At the cellular level it promotes tendon-fibroblast outgrowth, survival, and migration, with effects linked to FAK-paxillin signaling — the cell-adhesion pathway that governs how fibroblasts move into a healing site [5]. A distinct route touches growth biology without being growth hormone. BPC-157 dose- and time-dependently increased growth-hormone-receptor expression, at both mRNA and protein levels, in tendon fibroblasts; adding growth hormone to those sensitized cells then increased proliferation and PCNA expression [6]. Broader reviews position the peptide as a brain-gut-axis mediator that modulates serotonergic and dopaminergic systems and engages Egr-1, NAB2, FAK-paxillin, and JAK-2 signaling [8]. The study-level evidence behind these routes — including the [tendon and fibroblast findings](/research) — is laid out on the research page. ### How does BPC-157 work? Its repair effects are most consistently tied to angiogenesis driven by VEGFR2: BPC-157 up-regulates VEGFR2 and promotes its internalization, activating the VEGFR2-Akt-eNOS nitric-oxide pathway [3]. Additional reported routes include nitric-oxide-system and Src-Caveolin-1-eNOS vasomotor modulation [9], FAK-paxillin signaling for cell migration [5], growth-hormone-receptor sensitization in tendon fibroblasts [6], and effects on serotonergic and dopaminergic systems [8]. ### What is BPC-157's mechanism of action? The unifying mechanism is pro-angiogenic cytoprotection: VEGFR2 up-regulation and internalization feeding Akt-eNOS nitric-oxide signaling [3], complemented by NO-system and Src-Caveolin-1-eNOS vasomotor modulation [9], FAK-paxillin-linked fibroblast outgrowth [5], growth-hormone-receptor up-regulation in tendon fibroblasts [6], and Egr-1/NAB2/JAK-2 early-response signaling [8]. Pharmacokinetically the peptide shows linear PK and an elimination half-life under 30 minutes [2]. ## Pharmacokinetics: a sub-30-minute elimination half-life The first formal PK/ADME characterization of BPC-157, in rats and beagle dogs, reported linear pharmacokinetics across doses and a very short elimination half-life [2]. The half-life figure is under 30 minutes, after intravenous and intramuscular administration [2]. Intramuscular bioavailability landed around 14-19% in rats and 45-51% in dogs, with excretion via urine and bile, and the peptide broke down rapidly into small fragments entering normal amino-acid metabolism [2]. ### BPC-157 half life The BPC-157 half life — specifically the elimination half-life — is reported as under 30 minutes for the prototype peptide in the rat and dog PK study, across intravenous and intramuscular routes [2]. Intramuscular bioavailability was roughly 14-19% in rats and 45-51% in dogs [2]. The practical reading: the parent peptide does not accumulate, so any durable effect reflects the downstream angiogenic cascade rather than a maintained blood level. This is the figure that reframes every efficacy question. With clearance this fast, the relevant biology is not "how long does the drug stay up" but "what cascade did the brief exposure set in motion." That is also why this console treats the PK spine, not the dose, as the disciplining datum — and why [BPC-157 dosage in animal studies](/dosage) is presented as study-administered figures rather than schedules. --- A liquid-glass console reading of the peer-reviewed BPC-157 record — each datum refracted back to its source, the human-data gap left lit, and no clinic behind the panel.